Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aclaris Therapeutics, Inc. (ACRS)

NEW YORK, NY / ACCESSWIRE / July 31, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ:ACRS). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/acrs.

The investigation concerns whether Aclaris and certain of its officers and/or directors have violated federal securities laws.

On June 20, 2019, the U.S. Food & Drug Administration (“FDA”) asserted that an Aclaris advertisement for its Eskata hydrogen peroxide topical solution “makes false or misleading claims” regarding the product’s risk and efficacy. Specifically, the FDA stated that “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders . . . in the case of exposure to the eye and severe skin reactions including scarring.” On this news, Aclaris’s stock price fell sharply on June 21, 2019.

If you are aware of any facts relating to this investigation, or purchased Aclaris shares,you can assist this investigation by visiting the firm’s site: www.bgandg.com/acrs. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 554091